Generic drugs deliver a record $254 billion in savings to US health care system in 2014, new report shows

4 November 2015

The US health care system saved a record $254 billion in 2014 from generic drugs, which amounts to $1.68 trillion over the most recent decade (2005-2014), according to the seventh annual Generic Drug Savings in the United States report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).

"The facts are irrefutable, generic drugs drive enormous health care savings. This new report reinforces that generic drugs are a critical part of any solution to rising costs for patients, payers and for the entire healthcare system. Safe, effective and more affordable generic medicines mean increased access for the millions who rely on these life-saving therapies," said Chip Davis, president and chief executive of the GPhA.

For the first time, this year's report includes state-by-state savings from generics. It also details the key role generic drugs play in Medicare and Medicaid savings, resulting in billions of dollars of savings to federal and state budgets, beneficiaries and taxpayers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics